PTC Therapeutics reports new Sephience PKU trial and real-world data showing sustained Phe control, diet liberalization

Reuters2026/08/24 12:03

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

PTC Therapeutics outlined new Sephience (sepiapterin) trial and real-world analyses slated for presentation at the SSIEM meeting on Aug. 25-28.
Upcoming presentations point to sustained metabolic control in PKU, with many patients reaching normal-range blood phenylalanine quickly.
Data also suggest meaningful diet liberalization while maintaining recommended control, including in patients with more severe or historically less responsive disease.
Safety findings remained consistent with prior studies, supporting broader use across patient subgroups.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PTC Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608240800PR_NEWS_USPR_____NY31852) on August 24, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

PTC Therapeutics reports new Sephience PKU trial and real-world data showing sustained Phe control, diet liberalization

You may also like

Crypto prices